The insensitivity of RET-activated thyroid cancer cells to MEK inhibition has been previously demonstrated, as opposed to the high sensitivity of thyroid cancer cells expressing BRAFV600E[31]. The gene discussed is RET; the disease is thyroid gland carcinoma.